FAQ
Harassment Policy
Assessing the Aridhia DRE against the SATRE specification for 2026
This paper scores the Aridhia DRE against the four sections of the SATRE specification for 2026.
A formal assessment by the UK's data protection authority confirming the organisation's data handling practices align with current legislation.
DARE UK TREvolution Final Report
Aridhia's DARE UK TREvolution final report: federated TRE workspace integration, GA4GH Task Execution Service implementation, and Federated Node development.
An independently verified extension of Cyber Essentials, providing a higher level of assurance through hands-on technical testing.
This formal registration with the UK's data protection regulator confirms that our organisation processes personal data lawfully and transparently.
Aridhia's published papers and reports — SATRE specification scoring, DARE UK TREvolution, rare disease drug development, and TRE infrastructure research.
Delivering Regulatory Impact from Consortium-Based Projects
How consortium-based drug development programmes achieve regulatory milestones. Lessons from C-Path, IHI, and the RDCA-DAP platform built on the Aridhia DRE.
MIDD innovations for paediatric rare disease drug development, addressing small populations and patient heterogeneity. Published Clin Pharmacol Ther, 2025
